Bottom line
FHLC vs FSPHX: the short answer
FHLC (Fidelity MSCI Health Care Index ETF) and FSPHX (Health Care Portfolio) share a meaningful slice of their top holdings — about 48% by weight.
But FHLC is far broader, holding 337 positions to 152 for FSPHX, so beyond the top names it adds exposure FSPHX doesn't have.
FHLC is cheaper at 0.084% vs 0.62% — a difference of $54 a year per $10,000 invested.
Over five years, FHLC returned +7.2% a year vs +4.0% for FSPHX (reporting dates differ).
Updated Nov 19, 2026
FHLC vs FSPHX side by side
| FHLC | FSPHX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Fidelity | Fidelity |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.084% | 0.62% |
| Annual cost per $10k | $8.4 | $62 |
| 10-yr cost on $10k (prospectus) | $108 | $774 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +2.6% | +14.4% |
| 5-yr return (annualized) | +7.2% | +4.0% |
| 10-yr return (annualized) | +8.8% | +9.0% |
| Best quarter | +16.4% | +22.2% |
| Worst quarter | −13.1% | −15.0% |
| Net assets (fund) | $3.3B | $5.8B |
| Number of holdings | 337 | 152 |
| Portfolio turnover | 3% | 69% |
| Returns as of | Nov 30, 2025 | Apr 30, 2026 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FHLC | FSPHX | Difference |
|---|---|---|---|
| 2024 | +2.6% | +4.9% | −2.3% |
| 2023 | +2.5% | +4.1% | −1.7% |
| 2022 | −5.5% | −12.8% | +7.4% |
| 2021 | +20.4% | +11.5% | +8.9% |
| 2020 | +18.1% | +24.4% | −6.3% |
| 2019 | +21.9% | +31.5% | −9.5% |
| 2018 | +5.5% | +7.4% | −1.9% |
| 2017 | +23.3% | +24.0% | −0.7% |
| 2016 | −3.3% | −10.7% | +7.4% |
Source: Fund prospectus bar charts
Holdings overlap
11 of FHLC's top 25 holdings also appear in FSPHX's top 25.
| Holding | FHLC | FSPHX |
|---|---|---|
| Eli Lilly & Co | 13.35% | 8.03% |
| Johnson & Johnson | 8.93% | 4.91% |
| AbbVie Inc | 6.42% | 2.03% |
| UnitedHealth Group Inc | 5.44% | 3.49% |
| Merck & Co Inc | 4.66% | 1.60% |
| Thermo Fisher Scientific Inc | 3.09% | 4.33% |
| Gilead Sciences Inc | 2.34% | 2.21% |
| CVS Health Corp | 1.92% | 1.29% |
| Danaher Corp | 1.80% | 6.89% |
| Boston Scientific Corp | 1.00% | 2.17% |
| Cencora Inc | 0.83% | 1.14% |
Source: SEC Form N-PORT
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
FSPHX top 10
- ELI LILLY and CO — 8.03%
- Danaher Corp — 6.89%
- JOHNSON and JOHNSON — 4.91%
- Thermo Fisher Scientific Inc — 4.33%
- Unitedhealth Group Inc — 3.49%
- Alnylam Pharmaceuticals Inc — 2.40%
- Gilead Sciences Inc — 2.21%
- Boston Scientific Corp — 2.17%
- Ascendis Pharma A/s — 2.17%
- Fidelity Revere Street Trust — 2.17%
FAQ
What is the difference between FHLC and FSPHX?
Which is cheaper, FHLC or FSPHX?
Should I own both FHLC and FSPHX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.